Stryker's Q3 Miss and Cut Guidance Validate Sell Thesis, Stock Plunges

What happened

Stryker reported disappointing third-quarter results, with both earnings and sales falling short of consensus, triggering an 11.8% stock plunge and a cut to its 2026 outlook. The miss was driven by softer joint replacement procedures and execution challenges that underscored the risks flagged in our prior analysis, where rich valuation left little room for error. The master report had highlighted that although Stryker was a high-quality compounder, its premium multiple of ~46x earnings and DCF value near $124 implied significant downside if growth faltered. The latest news confirms that the anticipated pressure from tariffs, competition, and integration issues is now directly impacting financial performance, aligning with our previous 'potential sell' stance. With the stock now trading significantly lower, the market is beginning to reprice the shares toward a more reasonable valuation, but the fundamental concerns around growth durability and execution remain.

Implication

The earnings shortfall and reduced 2026 outlook directly undermine the double-digit growth and margin expansion assumptions embedded in the prior high multiple. With the stock still trading at a significant premium to intrinsic value, and now facing weaker procedure volumes and integration hurdles, the risk-reward remains unfavorable for long-term holders. The market's sharp reaction suggests investors are beginning to price in a more normalized growth rate, which could lead to continued de-rating toward historical averages. Existing shareholders should use any near-term rebounds to trim positions, while value-oriented investors may wait for further downside or clearer signs of stabilization in joint procedures and M&A execution. Monitoring upcoming quarters for any improvement in orthopaedic demand and cost controls will be key; failure to show progress could push the stock to our DCF-based fair value, implying substantial additional downside.

Thesis delta

The thesis shifts from potential sell (valuation-driven caution) to a more definitive sell based on confirmed fundamental deterioration. The miss and lowered guidance directly validate the earlier concerns about slowing joint procedures and integration risks, reducing confidence in the premium growth narrative. While the stock's 11.8% drop offers some relief from extreme valuation, it remains well above our DCF estimate, and the worsening outlook suggests further downside risk unless management can quickly stabilize execution.